Neurofilament light chain level is a weak risk factor for the development of MS
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. METHODS: Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. RESULTS: The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553.1 [1,208.7-1,897.5] ng/L and CIS-CIS 499.0 [168.8-829.2] ng/L, p < 0.0001). The strongest associations were with brain parenchymal fraction change (rs = -0.892) and percentage brain volume change (rs = -0.842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1.009, 95% CI 1.005-1.014) and McDonald MS (HR = 1.009, 95% CI 1.005-1.013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1.005, 95% CI 1.000-1.011). This risk was lower than the presence of oligoclonal bands or T2 lesions. CONCLUSIONS: NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationFisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
Self-citationDo oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Tintoré, M., Rovira, A., Río, J., Tur, C., Pelayo, R., Nos, C., Téllez, N., Perkal, H., Comabella, M., Sastre-Garriga, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000280576.73609.c6 · Cited by 345
Self-citationA comparative study of CSF neurofilament light and heavy chain protein in MS
Kuhle, J., Plattner, K., Bestwick, J. P., Lindberg, R. L., Ramagopalan, S. V., Norgren, N., Nissim, A., Malaspina, A., Leppert, D., Giovannoni, G., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513482374 · Cited by 155
Self-citationNeurofilament ELISA validation
Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M. A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., et al. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.09.014 · Cited by 105
Self-citation
Cited by
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Self-citationFilippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Neurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Self-citationReaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Self-citation
Metadata
- Authors
- Arrambide, G., Espejo, C., Eixarch, H., Villar, L. M., Alvarez-Cermeño, J. C., Picón, C., Kuhle, J., Disanto, G., Kappos, L., Sastre-Garriga, J., Pareto, D., Simon, E., Comabella, M., Río, J., Nos, C., Tur, C., Castilló, J., Vidal-Jordana, A., Galán, I., Arévalo, M. J., Auger, C., Rovira, A., Montalban, X., & Tintore, M.
- Venue
- Neurology
- Published
- 2016-09-13
- Volume
- 87
- Issue
- 11
- Pages
- 1076-1084
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2509699065
- Cited by
- 110
- References
- 7
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurofilament light chain level is a weak risk factor for the development of MS. https://app.cochat.ai/papers/10.1212/wnl.0000000000003085
- The paper
- Arrambide, G., Espejo, C., Eixarch, H., Villar, L. M., Alvarez-Cermeño, J. C., Picón, C., Kuhle, J., Disanto, G., Kappos, L., Sastre-Garriga, J., Pareto, D., Simon, E., Comabella, M., Río, J., Nos, C., Tur, C., Castilló, J., Vidal-Jordana, A., Galán, I., . . . Tintore, M. (2016). Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. https://doi.org/10.1212/wnl.0000000000003085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.